Rashes caused by arbidol in a patient with novel coronavirus pneumonia
10.3760/cma.j.cn114015-20200316-00281
- VernacularTitle:阿比多尔致新型冠状病毒肺炎患者皮疹
- Author:
Yu XIONG
1
;
Yuan BIAN
;
Xiting TANG
;
Rongsheng TONG
;
Xiaojiao CUI
;
Min JIANG
;
Zhiyong YANG
Author Information
1. 四川省医学科学院·四川省人民医院/电子科技大学附属医院药学部/个体化药物治疗四川省重点实验室，成都 610072；电子科技大学医学院，成都 600054
- Publication Type:Journal Article
- Keywords:
Coronavirus infections;
Skin rash;
Arbidol;
Novel coronavirus pneumonia
- From:
Adverse Drug Reactions Journal
2020;22(6):373-374
- CountryChina
- Language:Chinese
-
Abstract:
A 50-year-old male patient with agitated depression and hyperlipemia received oral amoxicillin and clavulanate potassium 0.5 g once daily and 2 lopinavir and ritonavir tablets twice daily for novel coronavirus infection, based on previous drugs including quetiapine, clonazepam, and atorvastatin calcium. After 3 days, lopinavir and ritonavir was changed to oral arbidol 200 mg, thrice daily due to suspicious drug interaction. After taking arbidol for 3 days, the patient developed red papules on the whole body. Considering that it might be related to amoxicillin and clavulanate potassium, the drug was stopped and loratadine was given. But the rashes were aggravated. Considering that the drug eruption was caused by arbidol, arbidol was discontinued and the rashes subsided in a large area the next day. Then vitamin C injection, calcium gluconate injection, and ribavirin were added. After 5 days, the rashes subsided completely. After 17 days, the patient recovered from pneumonia.
